Article
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer.
Nature communications - 19 Sept 2022
Johnson Radia M, Qu Xueping, Lin Chu-Fang, Huw Ling-Yuh, Venkatanarayan Avinashnarayan, Sokol Ethan, Ou Fang-Shu, Ihuegbu Nnamdi, Zill Oliver A, Kabbarah Omar, Wang Lisa, Bourgon Richard, de Sousa E Melo Felipe, Bolen Chris, Daemen Anneleen, Venook Alan P, Innocenti Federico, Lenz Heinz-Josef, Bais Carlos
Abstract excerpt
Most colorectal (CRC) tumors are dependent on EGFR/KRAS/BRAF/MAPK signaling activation. ARID1A is an epigenetic regulator mutated in approximately 5% of non-hypermutated CRC tumors. Here we show that anti-EGFR but not anti-VEGF treatment enriches for emerging ARID1A mutations in CRC patients. In addition, we find that patients with ARID1A mutations, at baseline, are associated with worse outcome when treated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.